CJC-1295: A Practical Guide

Overview

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) — the hypothalamic peptide that stimulates somatotroph cells in the anterior pituitary to release growth hormone. It consists of a modified 29-amino acid GHRH sequence with a Drug Affinity Complex (DAC) modification at the C-terminus in its most common commercial form. The DAC modification enables CJC-1295 to bind covalently to albumin in serum, dramatically extending its half-life from approximately 7–10 minutes (for native GHRH) to 6–8 days — transforming a practically unusable short-lived peptide into a clinically relevant long-acting GHRH analog. A shorter-acting version (CJC-1295 without DAC, sometimes called "Mod GRF 1-29") has a half-life of approximately 30 minutes and produces a sharper, more physiological GH pulse when combined with a GHRP-class agent. CJC-1295 (with DAC) produces sustained, elevated baseline GH/IGF-1 levels; CJC-1295 without DAC produces discrete GH pulses that more closely mimic natural pulsatile GH secretion. Key clinical distinction: CJC-1295 with DAC has a half-life of approximately 1 week — producing continuous GHRH receptor stimulation; "CJC-1295 without DAC" (Mod GRF 1-29) has a half-life of minutes and requires daily dosing. The two forms have meaningfully different protocols and risk profiles and should not be used interchangeably. Both forms stimulate pituitary GH release via GHRH receptors and are subject to somatostatin feedback regulation — preserving the hypothalamic-pituitary negative feedback that direct rhGH bypasses. In the US, CJC-1295 and Mod GRF 1-29 have been restricted from compounding by FDA regulatory actions (2023/2024); clinical and regulatory status varies by jurisdiction.

Mechanism of Action

GHRH receptor (GHRHR) agonism: CJC-1295 binds the GHRH receptor on somatotroph cells with high affinity. Receptor activation triggers cAMP/PKA signaling and IP3-mediated calcium mobilization, stimulating GH synthesis and secretion from secretory granules.

GH pulsatility (without DAC): Short-acting CJC-1295 without DAC, when injected SQ, produces a GH pulse within 15–30 minutes (peak), with return to baseline in 2–3 hours. This timing mirrors physiological GHRH release patterns.

Sustained IGF-1 elevation (with DAC): CJC-1295 with DAC, due to albumin binding, maintains elevated GHRH receptor stimulation continuously over days. This produces sustained IGF-1 elevation — a useful property for anabolic and body composition applications, though less physiologically pulsatile than natural GH secretion.

Preserved somatostatin feedback: Unlike direct rhGH injection, CJC-1295-stimulated GH secretion remains subject to somatostatin suppression. Elevated glucose, free fatty acids, and high IGF-1 trigger hypothalamic somatostatin release, which attenuates CJC-1295's effect on GH secretion — limiting runaway GH elevation. This is the primary theoretical safety advantage over exogenous rhGH.

Synergy with GHRP agents (Ipamorelin): GHRH receptor agonism (CJC-1295) and ghrelin receptor agonism (ipamorelin) act through separate but convergent intracellular pathways. Combined, they produce GH pulses 2–10× greater in amplitude than either agent alone — which is why CJC-1295 + ipamorelin is the most commonly prescribed combination in functional medicine GH optimization.

Evidence Base

Phase I/II pharmacokinetic data: Jetté et al. (2005, J Clin Endocrinol Metab): CJC-1295 with DAC (0.03–0.1 mg/kg SQ or IV) in healthy volunteers produced dose-dependent sustained IGF-1 increases (43–56% above baseline) lasting 9–11 days. Well tolerated at doses producing IGF-1 increases in the physiological range.

GH pulse physiology: Multiple studies have confirmed CJC-1295 without DAC preserves pulsatile GH secretion pattern when injected at bedtime, with peak GH occurring 30–45 minutes post-injection — aligning with the natural sleep-associated GH pulse.

Body composition and GHD analogy: Effects on body composition are extrapolated from rhGH and sermorelin literature — no large RCT specifically examining body composition outcomes with CJC-1295 in GH-deficient or GH-sufficient adults has been published. Reported IGF-1 elevations of 40–60% in functional medicine protocols reflect clinic-level observational tracking, not RCT data; the Jetté Phase I study (43–56%) is the only controlled human pharmacokinetic reference.

No completed human outcome RCTs for clinical endpoints (fracture prevention, cardiovascular outcomes, cancer incidence, mortality) have been published. All human evidence is pharmacokinetic/safety data.

Dosing & Timing

Food timing: Prandial insulin blunts GH secretory response to GHRH stimulation (via somatostatin). Inject on an empty stomach or at least 2 hours post-meal for maximum GH pulse amplitude.

Forms & Bioavailability

Lyophilized powder for SQ reconstitution. Reconstitute with bacteriostatic water; stable at 4°C for 28 days. SQ injection into abdomen or lateral thigh.

CJC-1295 with DAC vs without DAC: Different pharmacokinetic profiles (see above). Many products labeled "CJC-1295" do not specify DAC status — verify with supplier. The DAC-containing version is longer-acting and requires less frequent dosing; the DAC-free version is shorter-acting and preferred for pulsatile physiological mimicry.

Safety & Side Effects

Common: Water retention / mild edema (dose-dependent); transient headache; flushing; injection site reactions.

Glucose effects: GH elevation reduces insulin sensitivity. Monitor fasting glucose and HbA1c, particularly in prediabetic or T2DM individuals.

Cancer risk (theoretical): Sustained IGF-1 elevation raises the same theoretical oncological concern as rhGH. Avoid in patients with active malignancy or strong clinical suspicion thereof; any GH-axis therapy should keep IGF-1 within normal age-adjusted reference range.

Tachyphylaxis: Sustained pituitary stimulation with CJC-1295 DAC may reduce GHR receptor sensitivity over time — rationale for cycling CJC-1295 DAC vs using CJC without DAC for more intermittent pulsatile stimulation. Because DAC form accumulates with weekly dosing, overshooting IGF-1 is easier; start low, re-check IGF-1 after 6–8 weeks, and titrate.

Regulatory: FDA restricted CJC-1295 from 503A/503B compounding lists (2023/2024). Current legal sourcing requires clinical verification.

Drug & Supplement Interactions

Who Should Consider It

• Adults with low IGF-1 and clinical somatopause symptoms seeking GH axis optimization
• Those who prefer pulsatile, feedback-preserved GH stimulation over direct rhGH
• Functional medicine patients in GH optimization protocols

Bottom Line

CJC-1295 is the GHRH analog with the most pharmacokinetic validation in humans and the most widespread clinical use in functional GH optimization protocols. The DAC-containing version's combination of long half-life and preserved somatostatin feedback makes it practical and potentially safer than direct rhGH. The evidence base for CJC-1295 specifically is stronger than for most research peptides — but still limited to pharmacokinetic studies rather than clinical outcome trials. Its regulatory status in the US is currently restricted; practitioners and patients must navigate this carefully.

Last reviewed: 2026.